Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines, Inc. (RVMD)
:RVMD
Earnings Data
Report Date
Mar 02, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.59Last Year’s EPS
-1.12Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected strong progress in clinical programs and regulatory achievements for daraxonrasib, as well as a solid financial position supported by strategic partnerships. However, these positive developments were somewhat offset by increased operating expenses and significant net losses.Company Guidance
Positive Clinical Progress with Daraxonrasib
Daraxonrasib showed compelling clinical activity in pancreatic cancer, with an objective response rate of 47% as monotherapy and 55% when combined with chemotherapy. Disease control rates were 89% and 90% respectively.
Regulatory Achievements for Daraxonrasib
Daraxonrasib received three special designations from the FDA, including Breakthrough Therapy Status, Orphan Drug Designation, and a Commissioner's National Priority Voucher.
Strong Financial Position
Ended Q3 2025 with $1.93 billion in cash and investments, with an additional $1.75 billion in future committed capital from a partnership with Royalty Pharma.
Expansion and Strengthening of Global Operations
Key appointments across commercialization functions, including new regional leaders in the U.S. and European regions, as well as a new Chief Development Officer.
Promising Developments in Non-Small Cell Lung Cancer
Elironrasib demonstrated a confirmed objective response rate of 42% and a disease control rate of 79% in heavily pretreated non-small cell lung cancer patients.
RVMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RVMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $59.34 | $61.38 | +3.44% |
Aug 06, 2025 | $36.67 | $34.95 | -4.69% |
May 07, 2025 | $37.66 | $41.91 | +11.29% |
Feb 26, 2025 | $40.50 | $39.08 | -3.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Revolution Medicines, Inc. (RVMD) report earnings?
Revolution Medicines, Inc. (RVMD) is schdueled to report earning on Mar 02, 2026, After Close (Confirmed).
What is Revolution Medicines, Inc. (RVMD) earnings time?
Revolution Medicines, Inc. (RVMD) earnings time is at Mar 02, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVMD EPS forecast?
RVMD EPS forecast for the fiscal quarter 2025 (Q4) is -1.59.
